centro paulista de
alergia e imunopatologia

Bavarian Nordic and Adaptvac Sign Final License Agreement on Covid-19 Vaccine

  • Compartilhe
Publicado em 17 abr 2022

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Amidst the ongoing COVID-19 pandemic, the race for a safe and effective vaccine has become the topmost priority for various pharmaceutical and biotech companies around the world. One such update that recently made headlines is the final license agreement signed between Bavarian Nordic and AdaptVac for the development of a COVID-19 vaccine.

As per the agreement, Bavarian Nordic will utilize AdaptVac`s capsid virus-like particle (cVLP) technology to develop a potential COVID-19 vaccine. The technology involves the use of a synthetic virus-like particle that closely resembles the outer shell of the SARS-CoV-2 virus responsible for COVID-19. This particle can safely trigger an immune response in the human body, leading to the production of antibodies that can fight against the virus.

This collaboration between Bavarian Nordic and AdaptVac will enable the two companies to combine their expertise in the fields of vaccine development and virus-like particle technology. Together, they will work towards creating a vaccine that can offer long-lasting immunity against COVID-19.

Speaking about the agreement, Paul Chaplin, President, and CEO of Bavarian Nordic stated, “We are excited to be partnering with AdaptVac to develop a COVID-19 vaccine that has the potential to provide long-lasting immunity with a safe and simple dosing regimen. This collaboration underlines our commitment to meeting the global healthcare needs in the ongoing fight against the COVID-19 pandemic.”

Similarly, Peter Holst, CEO of AdaptVac, expressed his optimism stating, “We are thrilled to work with Bavarian Nordic to develop a vaccine that addresses the significant unmet need for long-term protection against COVID-19. The combination of our cVLP technology with Bavarian Nordic`s expertise in vaccine development and manufacturing makes us confident that we can deliver a safe and effective vaccine.”

The COVID-19 pandemic has caused widespread panic and chaos, disrupting the normal way of life for millions of people across the globe. The need for a vaccine that can fight against the virus has become more critical than ever. With the signing of the final license agreement between Bavarian Nordic and AdaptVac, there is hope for the development of a successful vaccine that can help us overcome this health crisis.

In conclusion, the collaboration between Bavarian Nordic and AdaptVac for the development of a COVID-19 vaccine is a significant step forward in the fight against the pandemic. With their collective expertise and resources, there is optimism that a safe and effective vaccine can soon be made available to the public, bringing an end to this global health crisis.